Replies to post #790023 on NorthWest Biotherapeutics Inc (NWBO)

[seekinganswers]

"actively engaged "
LOL, I am actively engaged in the next Powerball drawing.

[Flexroy]

Hey DD, thanks for your post. I hardly ever reply to this board anymore but I appreciate fellows like yourself who keep the home fires burning and keep us on track for what is Hopefully approval soon. Best.

[seekinganswers]

LOL
Danish doofus.
Did you get MHRA approval yet , after 620 days? Tell us all about the external control scam..... Please do.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10076936/
https://www.sciencedirect.com/science/article/pii/S0035378723009190?via%3Dihub

Good Luck scammer. Gee, I wonder why it's never ever getting approved... Hmmm

*** "9. Conclusion
This dendritic vaccine trial has several limitations. These limitations include changing the primary endpoint (OS instead of PFS), creating a new study population (recurrent glioblastoma), conducting unplanned analyses, using external controls in a design originally intended to be randomized, all changes occurring years after the trial finished enrollment. The selected external controls likely included patients with less favorable outcomes, which opposes the “fit-for-purpose” criteria usually applied in selecting external controls. Therefore, the purported survival benefit from the vaccine is unreliable. The accumulation of limitations, along with multiple changes made over nearly two decades; further hamper the reliability of the reported results. Without data sharing, those concerns cannot be alleviated. Glioblastoma is the most common primary brain tumor, and there is no valid reason to stray from the gold standard of a randomized-controlled trial with overall survival as the primary endpoint in order to change clinical practice. Dendritic cell vaccination is a very promising approach for GBM, the neuro-oncology medical community can only regret that due to the described DCVax-L trial weaknesses, we cannot draw any conclusions on potential efficacy.